| Trial | Sponsor | Phase | Status | Primary completion |
|---|
| Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic DrugNCT06641076 | MoonLake Immunotherapeutics AG | Phase 3 | Active not recruiting | 2026-05-28Actual |
| Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate ResponseNCT06641089 | MoonLake Immunotherapeutics AG | Phase 3 | Active not recruiting | 2027-01-04Estimated |
| Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).NCT06641414 | Ascentage Pharma Group Inc. | Phase 3 | Recruiting | 2029-06Estimated |
| A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and EfficacyNCT06643260 | Can-Fite BioPharma | Phase 3 | Not yet recruiting | 2027-12Estimated |
| Suprachoroidal Administration in Subjects With Metastases to the ChoroidNCT06643884 | Aura Biosciences | Phase 2 | Recruiting | 2026-11-30Estimated |
| A Study to Assess TTI-0102 vs Placebo in MELAS PatientsNCT06644534 | Thiogenesis Therapeutics, Inc. | Phase 2 | Completed | 2026-01-12Actual |
| Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell TherapiesNCT06652633 | LKFT | Phase 3 | Recruiting | 2039-07Estimated |
| A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous MalformationsNCT06653842 | PVLA | Phase 2 | Active not recruiting | 2025-11-21Actual |
| B-FREE Chronic Babesiosis StudyNCT06656351 | 60 Degrees Pharmaceuticals LLC | Phase 2 | Recruiting | 2027-02Estimated |
| ALTO-100 in Bipolar Disorder With Depression (BD-D)NCT06656416 | Alto Neuroscience | Phase 2 | Recruiting | 2027-09Estimated |
| A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBCNCT06663137 | RLMD | Phase 2 | Recruiting | 2027-11Estimated |
| A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1NCT06667453 | PEPG | Phase 2 | Recruiting | 2027-03Estimated |
| A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 InfectionNCT06672055 | Vaxart | Phase 2 | Active not recruiting | 2027-05Estimated |
| A Phase 3 Study of NTLA-2001 in ATTRv-PNNCT06672237 | Intellia Therapeutics | Phase 3 | Active not recruiting | 2027-07Estimated |
| A Rollover Study to Evaluate the Long-Term Safety and Efficacy of AtaciceptNCT06674577 | VERA | Phase 2 | Enrolling by invitation | 2031-05-21Estimated |
| A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic CancerNCT06678659 | RXRX | Phase 1, Phase 2 | Recruiting | 2029-07Estimated |
| Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AMLNCT06679582 | STRO | Phase 1, Phase 2 | Terminated | 2025-01-21Actual |
| A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular CarcinomaNCT06679985 | CHRS | Phase 2 | Active not recruiting | 2027-09Estimated |
| A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic TherapyNCT06680258 | Tempest Therapeutics | Phase 3 | Not yet recruiting | 2028-12Estimated |
| A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese PatientsNCT06682572 | VSTM | Phase 2 | Active not recruiting | 2025-12Estimated |
| A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 MutationNCT06682806 | Prelude Therapeutics Incorporated | Phase 2 | Terminated | 2026-01-23Actual |
| A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)NCT06685692 | ALDX | Phase 2 | Completed | 2025-06-18Actual |
| 52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With HypogonadismNCT06689085 | Halozyme Therapeutics | Phase 3 | Recruiting | 2028-03Estimated |
| Controlled Study, Performed to Evaluate the Safety and Efficacy of EscharEx and Its Placebo (Gel Vehicle) Compared to Non-surgical Standard of Care in Participants With Venous Leg Ulcers (VLU)NCT06690177 | MDWD | Phase 2 | Not yet recruiting | 2028-11-04Estimated |
| A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsNCT06695845 | Jazz Pharmaceuticals | Phase 2 | Recruiting | 2026-12-31Estimated |
| A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated With the INTERCEPT Blood System for Platelets With LED Illuminator.NCT06697223 | Cerus Corporation | Phase 2 | Completed | 2025-06-02Actual |
| Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.NCT06697301 | Eikon Therapeutics | Phase 2, Phase 3 | Recruiting | 2035-12Estimated |
| CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched RegimenNCT06699836 | CytoDyn, Inc. | Phase 2 | Active not recruiting | 2028-01Estimated |
| Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 VariantNCT06701396 | Vanda Pharmaceuticals | Phase 3 | Recruiting | 2025-06-30Estimated |
| CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)NCT06708299 | CRDL | Phase 3 | Recruiting | 2026-09-21Estimated |
Trial details
- Registry ID
- NCT06641076
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06641089
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06641414
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06643260
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06643884
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06644534
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06652633
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06653842
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06656351
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06656416
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06663137
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06667453
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06672055
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06672237
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06674577
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06678659
- Phase
- Phase 1, Phase 2
Trial details
- Registry ID
- NCT06679582
- Phase
- Phase 1, Phase 2
Trial details
- Registry ID
- NCT06679985
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06680258
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06682572
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06682806
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06685692
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06689085
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06690177
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06695845
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06697223
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06697301
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT06699836
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06701396
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06708299
- Phase
- Phase 3
Primary completion marks the end of data collection for the main study measures, not a results publication date.